Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
20/20 BiolabsAIDX -0.23%6 PB Ratio is 1.73 as of Aug. 04, 2026, which is 51% below its 10-year median of 3.55. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 788 Medical Devices & Instruments companies, 20/20 Biolabs ranks better than 56.85% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-04), 20/20 Biolabs's share price is $0.4215. 20/20 Biolabs's Book Value per Share for the quarter that ended in Mar. 2026 was $0.24. Hence, 20/20 Biolabs's PB Ratio of today is 1.73.
Good Sign:
20/20 Biolabs Inc stock PB Ratio (=1.73) is close to 1-year low of 1.73.
The historical rank and industry rank for 20/20 Biolabs's PB Ratio or its related term are showing as below:
AIDX'
s PB Ratio Range Over the Past 10 Years
Min: 1.73 Med: 3.55 Max: 7.7
Current: 1.73
During the past 3 years, 20/20 Biolabs's highest PB Ratio was 7.70. The lowest was 1.73. And the median was 3.55.
AIDX's PB Ratio is ranked better than 56.85% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs AIDX: 1.73
During the past 12 months, 20/20 Biolabs's average Book Value Per Share Growth Rate was -104.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
20/20 Biolabs PB Ratio Related Terms
20/20 Biolabs PB Ratio Historical Data
* Premium members only.
The historical data trend for 20/20 Biolabs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, 20/20 Biolabs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
20/20 Biolabs PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 20/20 Biolabs's PB Ratio distribution charts can be found below:
* The bar in red indicates where 20/20 Biolabs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
20/20 Biolabs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
20/20 Biolabs (AIDX) has a PB Ratio of 1.73 as of Aug. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on 20/20 Biolabs and its competitors. This is 51% below median its historical median of 3.55. Over the past decade, 20/20 Biolabs' PB Ratio has ranged from 1.73 to 7.70. According to the industry distribution chart, 20/20 Biolabs ranks #340 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 43.1%.
Is 20/20 Biolabs' PB Ratio too high?
20/20 Biolabs' current PB Ratio of 1.73 is 51% below median its 10-year median of 3.55. Over the past 10 years, this metric has ranged from a low of 1.73 to a high of 7.70. The Medical Devices & Instruments industry median PB Ratio is 2.07. 20/20 Biolabs' value of 1.73 is 16.4% below this industry median. Based on the distribution chart, 20/20 Biolabs ranks #340 out of 788 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' PB Ratio compare to STME and TRIB?
According to the Medical Devices & Instruments industry distribution chart, 20/20 Biolabs ranks #340 out of 788 companies for PB Ratio. This puts 20/20 Biolabs in the upper half of its industry. The industry median PB Ratio is 2.07. 20/20 Biolabs' value of 1.73 is 16.4% below this benchmark. Historically, 20/20 Biolabs' own PB Ratio has ranged from 1.73 to 7.70 over the past decade. While the company's 10-year median is 3.55 vs. the industry median of 2.07, 20/20 Biolabs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.07, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 20/20 Biolabs's current PB Ratio of 1.73 is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on 20/20 Biolabs and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 20/20 Biolabs's current PB Ratio is 1.73, which is 51% below median its own 10-year median of 3.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current PB Ratio of 1.73. The current PB Ratio is 1.73, which is 51% below median its 10-year median of 3.55 and 16.4% below the Medical Devices & Instruments industry median of 2.07. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current PB Ratio is 1.73 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score
Get the complete analysis for AIDX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIDX has been successfully added to your 
